Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

BOSTON--(BUSINESS WIRE)-- Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that preclinical data from its oncogenic driver program targeting KRAS G12D, AFNT-212, will be presented at the Society for Immunotherapy of Cancer (SITC) 38^th Annual Meeting.

“Gene editing is a key piece of our overall strategy to develop precision immunotherapies for patients with hard-to-treat solid tumors,” said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. “Our data show that non-viral targeted knock-in engineered AFNT-212 T cells drive a robust coordinated CD4+ CD8+ T cell immune response against KRAS G12D mutated tumors with promising preclinical activity and tolerability, supporting the planned clinical development of our AFNT-212 T Cell Receptor-engineered therapy. We look forward to presenting these findings at SITC.”

Poster presentation details are as follows:

Title: Directing a high avidity KRAS G12D-specific TCR engineered with a CD8αβ co-receptor and chimeric cytokine receptor using non-viral knock-in enhances anti-tumor responses
Abstract no: 355
Presenting Author: Ankit Gupta, Ph.D., Senior Director, Gene Editing, Affini-T Therapeutics
Date/Time: Friday, November 3, 2023, 12:00 pm – 1:30 pm and 5:10 pm – 6:40 pm PT

Title: Non-viral targeted knock-in of a KRAS G12D specific TCR, CD8αβ, and chimeric cytokine receptor in the TRAC locus outperforms lentiviral-based engineering of T cells
Abstract no: 1223
Presenting Author: Allison P. Drain, Ph.D., Senior Scientist, Synthetic Biology, Affini-T Therapeutics
Date/Time: Friday, November 3, 2023, 12:00 pm – 1:30 pm and 5:10 pm – 6:40 pm PT

About Affini-T Therapeutics

Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology, and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231031001551/en/